CardioSignal makes reliable heart disease detection available to smartphone users. An ambitious cybersecurity strategy is crucial to achieve accessibility and trust in new remote care models the company is developing with its customers globally.

With results that compare well with existing clinical methods, this study demonstrates the value of using motion sensor technology, available in most commercial smartphones today, for the detection of clinical heart failure. The multi-site study was conducted at three hospitals, including Stanford University Hospital, Turku University Hospital, and Helsinki University Hospital.

The study of >1000 patients reached its primary endpoint of recognizing clinical heart failure with smartphone-based technology. Comprehensive results of the study will be published later in 2022.

CardioSignal, a health technology company developing motion sensor technology to improve heart disease detection, was announced a winner in the Innovation Pitch Challenge by American College of Cardiology's Annual Scientific Session & Expo 2022 in Washington D.C. on April 3, 2022. The Pitch Challenge was organized in partnership with the National Heart Lung and Blood Institute (NHLBI).

To enable the early detection of atrial fibrillation and subsequent intervention, Mehiläinen and CardioSignal are collaborating to build a digital health approach that includes offering home monitoring to at-risk individuals in Finland. Early detection of atrial fibrillation has the potential to significantly reduce future hospitalizations from heart failure or stroke.

The collaboration includes making easy-to-use, at-home monitoring of atrial fibrillation available for at-risk individuals in France through a network of 1,000 cardiologists. The initiative aims to reach 5,000 individuals to prevent adverse health outcomes caused by undiagnosed atrial fibrillation.